The US FDA Grants Approval for Initiating the Study of USGI Medical’s POSE2.0 Incisionless Weight Loss Procedure for Primary Obesity
Shots:
- The US FDA has approved USGI Medical’s IDE application to commence a pivotal trial of its POSE2.0 incisionless procedure for primary obesity
- The INSPIRO study [Incisionless Suture Plications (POSE2.0) In a Randomized Obesity Study] will assess up to 186 patients across the US sites and other locations
- POSE2.0, using the Incisionless Operating Platform (IOP), shortens and narrows the stomach by placing Snowshoe Suture Anchors into the gastric tissue, offering volumetric gastric restriction without surgical removal of stomach parts. Patients resume their normal activities faster with this treatment when compared to conventional laparoscopic and open abdominal surgery
Ref: Globenewswire | Image: USGI Medical
Related News:- Innovent Reports the Results of Mazdutide (IBI362) in P-III Trial for the Treatment of Adults with Overweight or Obesity
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
